Evaluation of radiation-induced genotoxicity on hu-man melanoma cells (SK-MEL-37) by flow cytometry
DOI:
https://doi.org/10.15392/bjrs.v7i2A.572Palavras-chave:
micronucleus assay, melanoma, radiation, genotoxic damage..Resumo
Micronucleus assay is a test used to evaluate genotoxic damage in cells, which can be caused by various factors, like ionizing radiation. Interactions between radiation energies and DNA can cause breakage, leading to use chromosomal mutations or loss of genetic material, important events that could be induced in solid tumors to mitigate its expansion within human body. Melanoma has been described as a tumor with increased radio resistance. This work evaluated micronuclei percentages (%MN) in human melanoma cells (SK-MEL-37), irradiated by gamma radiation, with doses between 0 and 16Gy. Cell suspensions were irradiated in PBS by a 60Co source in doses between 0 and 16Gy, and incubated by 48h. Then cell membranes were lysed in the presence of SYTOX Green and EMA dyes, preserving nuclear membranes. Using this method, EMA-stained nuclei could be discriminated as those derived from dead cells, and SYTOX nuclei and micronuclei could be quantified. Micronuclei percentages were found to be proportional to dose, (R2 = 0.997). Only the highest dose (16Gy) could induce statistically significant increase of MN (p<0.0001), although cultures irradiated by 4, 8 and 16Gy showed significant increase of dead cell fractions. Calculation of the nuclei-to-beads ratio showed that 8 and 16Gy could reduce melanoma cell proliferation. Results showed that although cell death and loss of proliferative capacity could be observed on cultures irradiated at lower doses, genotoxic damage could be induced only on a higher dose. Resistance to radiation-induced genotoxicity could explain a relatively high radio resistance of melanoma tumors.
Downloads
Referências
INCA – The National Cancer Institute José Alencar Gomes da Silva. Estimate/2016 – Cancer Incidence in Brazil, Rio de Janeiro, Brazil. 2015. Avaliable at: <http://www.inca.gov.br/estimativa/2016/estimativa-2016-v11.pdf>. Last accessed: 10 May 2017.
MAHADEVAN, A., PATEL, V. L., DAGOGLU, N. Radiation Therapy in the Management of Malignant Melanoma. Oncology (Williston Park), v. 29, p.743–751, 2015.
WHO - World Health Organization. Skin cancers. Avaliable at: <http://www.who.int/uv/faq/skincancer/en/index1.html >. Last accessed: 10 May 2017.
INCA – The National Cancer Institute José Alencar Gomes da Silva. Atlas On-line de Mortalidade. Avaliable at: <https://mortalidade.inca.gov.br/MortalidadeWeb/pages/Modelo01/consultar.xhtml>. Last accessed: 10 May 2017.
National Collaboration Centre for Cancer. Melanoma : assessment and management - NICE guideline NG14: Full guideline. p. 87. 2015. Avaliable at: <http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0079031/pdf/PubMedHealth_PMH0079031.pdf>. Last accessed: 10 May 2017.
SHELLEDY, L.; ROMAN, D. Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma. Journal of the Advanced Practctitioner in Oncology, v. 6, p. 361–5, 2015
Zhu, Z.; Liu, W.; Gotlieb, V. The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond. Critical Reviews in Oncology/ Hematology, v. 99, p. 91-99, 2016.
ATKINS, M. Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Mela-noma: Current Approaches and Future Directions. Seminars in Oncology, v. 42, p. S12-S19, 2015.
FERTIL, B.; MALAISE, E.P. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. International Journal of Radiation Oncology*Biology*Physics, v. 11, p. 1699 – 707, 1985.
SAUSE, W.T.; COOPER, J.S.; RUSH, S.; AGO, C.T.; COSMATOS, D.; COUGHLIN, C.T.; JANJAN, N.; LIPSETT, J. Fraction size in external beam radiation therapy in the treatment of melanoma. International Journal of Radiation Oncology*Biology*Physics. v. 20, p. 429 – 32, 1991.
STEVENS, G.; MCKAY, M.J. Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma, The Lancet Oncology, v. 7, p. 575 – 83, 2006.
CHANG, D.T.; AMDUR, R.J.; MORRIS, C.G.; MENDENHALL, W.M. Adjuvant radio-therapy for cutaneous melanoma: Comparing hypofractionation to conventional fractionation. In-ternational Journal of Radiation Oncology*Biology*Physics,v. 66, p.1051–5, 2006.
GUADAGNOLO, B.A.; ZAGARS, G.K. Adjuvant radiation therapy for high-risk nodal metastases from cutaneous melanoma. The Lancet Oncology, v. 10, p. 409-16, 2009.
HENDERSON M.A.; BURMEISTER, B.H.; AINSLIE, J.; FISHER, R.; DI IULIO, J.; SMITHERS, B.M.; HONG, A.; SHANNON, K.; SCOLYER R.A.; CARRUTHERS, S.; COVEN-TRY, B. J.; BABINGTON, S.; DUPRAT, J.; HOEKSTRA, J.; THOMPSON, J. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial, The Lancet Oncology, v. 16, p.1049–60, 2015.
SPEIT, G.; ZELLER, J.; NEUSS, S. The in vivo or ex vivo origin of micronuclei measured in human biomonitoring studies. Mutagenesis, v. 26, p. 107–110, 2011.
HEDDLE, J. A.; FENECH, M.; HAYASHI, M.; MAC GREGOR. Reflections on the development of micronucleus assays. Mutagenesis, v. 26, p. 3–10, 2011.
OCAMPO I.Z.; PASSOS, P.Q.S.; DE CARVALHO, L. R.; DA CRUZ, C.A.L.; ESTEVES-PEDRO, N. M.; DA SILVA, F.M.; HIGA, O. Z.; DIAS, L.A.P.; OKAZAKI, K.; VIEIRA, D. P. In vitro cytotoxic and genotoxic evaluation of peptides used in nuclear medicine (DOTATATE and Ubiquicidin(29-41)) in CHO-K1 cells, Cytotechnology, v. 68, p. 2301-2310, 2016.
BRYCE, S. M.; , BEMIS, J. C.; AVLASEVICH, S.L. DERTINGER SD.In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, v. 630, p. 78-91, 2007.
Garty, G.; Bigelow, A. W.; REPIN, M.; TURNER, H. C.; BIAN, D.; BALAJEE, A.S.; LYULKO, A. S.; TAVERAS, M.; YAO, Y. L.; BRENNER, D. J. An automated imaging system for radiation biodosimetry. Microscopy Research and Technique, v. 598, p. 587 – 598, 2015.
HALL, E. J.; ASTOR, M.; BEDFORD, J. Basic radiobiology. American journal of clinical oncology, v. 11, p. 220 – 252, 1988.
Downloads
Publicado
Edição
Seção
Licença
Direitos autorais (c) 2021 Brazilian Journal of Radiation Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade. Declaro, ainda, que uma vez publicado na revista Brazilian Journal of Radiation Sciences, editada pela Sociedade Brasileira de Proteção Radiológica, o mesmo jamais será submetido por mim ou por qualquer um dos demais co-autores a qualquer outro periódico. Através deste instrumento, em meu nome e em nome dos demais co-autores, porventura existentes, cedo os direitos autorais do referido artigo à Sociedade Brasileira de Proteção Radiológica, que está autorizada a publicá-lo em meio impresso, digital, ou outro existente, sem retribuição financeira para os autores.
Licença
Os artigos do BJRS são licenciados sob uma Creative Commons Atribuição 4.0 Licença Internacional, que permite o uso, compartilhamento, adaptação, distribuição e reprodução em qualquer meio ou formato, desde que você dê o devido crédito ao (s) autor (es) original (is) e à fonte, forneça um link para a licença Creative Commons, e indique se mudanças foram feitas. As imagens ou outro material de terceiros neste artigo estão incluídos na licença Creative Commons do artigo, a menos que indicado de outra forma em uma linha de crédito para o material. Se o material não estiver incluído no licença Creative Commons do artigo e seu uso pretendido não é permitido por regulamentação legal ou excede o uso permitido, você precisará obter permissão diretamente do detentor dos direitos autorais. Para visualizar uma cópia desta licença, visite http://creativecommons.org/licenses/by/4.0/
